Focal adhesion kinase (p125 FAK ; 'FAK') is a tyrosine kinase that is localised to cellular focal adhesions and is associated with a number of other proteins, such as integrin adhesion receptors. We performed an immunohistochemical analysis of FAK protein expression to determine the relationship between FAK overexpression and clinicopathological factors in oesophageal squamous cell carcinoma (ESCC). We examined tissue specimens that had been removed from 91 patients with thoracic oesophageal cancer who had undergone surgery between 1983 and 2001. Immunohistochemical staining was performed by the standard streptavidin -biotin method. Seven human ESCC cell lines -TE-1, TE-2, TE-8, TE-13, TE-15, TT, and TTn -and one immortalized human keratinocyte cell line -HaCaT -were used in Western blot analysis. Immunostaining of FAK was seen in the cytoplasm of cancer cells, particularly in cells located in the invasive fronts of cancer nests. FAK overexpression was detected in 54 of the 91 patients (59.3%). Significant correlations were observed between FAK overexpression and cell differentiation (P ¼ 0.0057), depth of tumour invasion (P ¼ 0.0023), presence of regional lymph node metastasis (P ¼ 0.0097), number of lymph node metastases (P ¼ 0.0026), and disease stage (P ¼ 0.012). The survival rates of patients with FAK-overexpressing cancer were significantly lower than those of patients without FAK-overexpression cancer (P ¼ 0.006). The 5-year survival rate of patients without FAK overexpression was 69%, whereas that of patients with FAK overexpression was 38%. On Western blot analysis, FAK was expressed at a high level in TE-1, TE-8, TE-15, and TT cells, at a moderate level in TE-2 and TTn cells, and at a low level in TE13 and HaCaT cells. FAK phosphorylation at tyrosine 397 was demonstrated in proportion to the intensity of FAK in all cell lines except TE15 and HaCaT. In conclusion, FAK overexpression of ESCC was related to cell differentiation, tumour invasiveness, and lymph node metastasis. Consequently, patients with ESCC who had FAK overexpression had a poor prognosis.
Cancer invasion and metastasis are complex processes that include changes in cell adhesion, allowing transformed cells to invade and migrate through the extracellular matrix (Liotta et al, 1991) . These adhesions are mediated in part through the integrin family of cell surface receptors. Integrins are partly localised on the ventral surfaces of clusters called focal adhesions (Burridge et al, 1988) . Focal adhesion kinase (p125 FAK , hereafter referred to as FAK), is a tyrosine kinase that is localised to cellular focal adhesions and is associated with a number of other proteins, such as the integrin adhesion receptors (Richardson and Parsons, 1995) . The first indication that FAK might be involved in tumorigenesis came from the observation that it was one of several highly tyrosinephosphorylated proteins in src-transformed fibroblasts (Kanner et al, 1990; Schaller et al, 1992) . In normal cells, FAK is the major tyrosine-phosphorylated protein present in cells upon activation of the integrin receptors (Guan et al, 1991) . FAK is involved in integrin-signalling pathways (Kornberg et al, 1992; Lipfert et al, 1992; Schlaepfer et al, 1994) , cellular motility (Cary et al, 1996; Guan, 1997) , and apoptosis (Frisch et al, 1996; Hungerford et al, 1996; Xu et al, 1996) . Cells derived from pp125 FAK À/À mouse embryos exhibit reduced migration as a result of impaired adhesion turnover (Ilic et al, 1995 (Ilic et al, , 1996 . Overexpression of FAK has been reported in a number of invasive human cancer cells (Weiner et al, 1993; Akasaka et al, 1995; Owens et al, 1995; Tremblay et al, 1996; McCormack et al, 1997; Cance et al, 2000) . In some of these reports, there is a suspected relationship between FAK expression and metastatic ability.
There have been many studies of FAK expression in cancer cell lines and cancer tissues. However, few investigations have used immunohistochemical analysis, because almost all anti-FAK antibodies are ineffective for staining formaldehyde-fixed paraffin-embedded tissue sections (Cance et al, 2000) . There have been no reports of FAK expression in oesophageal squamous cell carcinoma (ESCC). We investigated FAK protein expression in ESCC by immunohistochemical analysis using FAK-specific monoclonal antibody 4.47 (Upstate Biotechnology Inc., Lake Placid, NY, USA) (Cance et al, 2000) . Our aim was to determine the relationship between FAK overexpression and clinicopathological factors in ESCC. Further, we used Western blot analysis to elucidate FAK overexpression and signal transduction in ESCC cell lines.
MATERIALS AND METHODS

Patients and tissue samples
The tissue specimens used had been removed from 91 patients with thoracic ESCC who had undergone surgery at the Gunma University Hospital between 1983 and 2001. Written informed consent to participate in the study was obtained from each patient before surgery, according to the ethical guidelines of our university. All patients underwent potentially curative surgery without preoperative therapy. There were 77 men and 14 women, aged 40À78 years (mean age: 61.0 years). Tumour stages were classified according to the 5th edition of the TNM classification of the International Union against Cancer (UICC). The evaluation of tumour differentiation was based on histological criteria of the guidelines of the Japanese Society for Esophageal Diseases (Japanese Society for Esophageal Diseases, 1999) . The mean postoperative follow-up period was 33.9 months (range: 6.2À192.2 months).
Specimens were fixed in 10% formaldehyde solution and embedded in paraffin. We examined sections that contained both a tumour-invasive portion and normal oesophageal epithelium.
Cell lines
Seven human oesophageal cancer cell lines -TE-1, TE-2, TE-8, TE-13, TE-15, TT, and TTn -and one spontaneously immortalised human keratinocyte cell line -HaCaT -were used. The TE cell lines were kindly provided by Dr T Nishihira (Institute of Development, Aging and Cancer, Tohoku University School of Medicine, Sendai, Japan) . TT and TTn cells (JCRB0262 and 0261) were kindly provided by Dr K Takahashi (Takahashi et al, 1990) . All cancer cell lines were derived from ESCC with varying degrees of differentiation . TE-1, TE-15, TT, and TTn were well-differentiated squamous cell carcinoma (SCC) in primary lesions. TE-8 was moderately differentiated SCC and TE-2 and TE-13 were poorly differentiated SCC. The TE cell lines were established from surgical specimens of the primary lesions. The TT cell line was obtained directly from a surgical specimen of a metastatic lesion in the mandible. The TTn cell line was established from a transplanted tumour in a nude mouse, the primary lesion being the same as that from which the TT cell line was established. It has been reported that all these cell lines were transplantable in nude mice (Takahashi et al, 1990; Galiana et al, 1993; Nishihira et al, 1993) . TE-2, TE-8, and TE-13 have the wild type of p53 (Barnas et al, 1997; Itoshima et al, 2000; Akimoto et al, 2001) . Regarding the p53 status of TE-1 and TTn, a mutation at codon 272 was reported, respectively (Barnas et al, 1997; Itoshima et al, 2000) . In TE-15, a heterozygous G-to-A mutation was detected in the splice-acceptor site of intron 5 of p53 (Barnas et al, 1997) . TE cell lines were cultured in RPMI-1640 medium (Sigma, St Louis, MO, USA) supplemented with 10% foetal bovine serum and antibiotics (100 U ml À1 penicillin and 100 mg ml À1 streptomycin). TT and TTn were cultured in 1 : 1 Dulbecco's modified Eagle medium (DMEM) and Ham's F-12 medium (Sigma) containing 10% foetal bovine serum and antibiotics, as described above. HaCaT was cultured in DMEM medium (Sigma) containing 10% foetal bovine serum and antibiotics, as described above. All cell lines were cultured to 60À80% confluence.
Antibodies
Antibodies were purchased from the following manufacturers: monoclonal antibody (Mab) specific for FAK (clone 4.47), (Upstate Biotechnology Inc., Lake Placid, NY, USA); rabbit polyclonal antibody specific for FAK-phosphorylated at tyrosine 397 (FAK [-pY 397 ]), (BioSource International Inc., Camarillo CA, USA); Mab specific for Ki-67 (MIB-1) (Immunotech, Marseille, France); Mab specific for b-actin, Sigma.
Immunohistochemistry for FAK protein and Ki-67 protein
Immunohistochemical staining was performed by the standard streptavidin -biotin (SAB) method. Briefly, each 4-mm tissue section was deparaffinised, then rehydrated and incubated with fresh 0.3% H 2 O 2 in methanol for 30 min at room temperature. After rehydration through a graded ethanol series, the sections were autoclaved in 1 mM EDTA buffer (pH 8.0) at 1201C for 5 min for anti-FAK Mab and were autoclaved in 10 mM citrate buffer (pH 6.0) at 1201C for 5 min for anti-Ki-67 FAK Mab , then cooled to 301C. After incubation with normal rabbit serum for 30 min, the tissue sections were removed by blotting. The sections were then incubated at 41C overnight with anti-FAK Mab at a dilution of 1 : 1000 in phosphate-buffered saline (PBS) containing 1% bovine serum albumin, then washed in PBS and incubated with secondary antibody for 30 min at room temperature. Immunohistochemistry was performed using a Histofine SAB-PO(M) kit (Nichirei, Tokyo, Japan). The chromogen was 3,3 0 -diaminobenzidine tetrahydrochloride, applied as a 0.02% solution containing 0.0055% H 2 O 2 in 50 mM ammonium acetate -citric acid buffer (pH 6.0). The sections were lightly counterstained with hematoxylin. Negative controls were prepared by substituting normal mouse serum for primary antibody, and no detectable staining was evident.
Evaluation of immunostaining for FAK and Ki-67 labelling index
When 440% of carcinoma cells in a given specimen were stained more intensely than the normal epithelium in the same section, the sample was classified as FAKoverexpression (FAK( þ ) ). Ki-67 labelling index was calculated as the percentage of nuclear staining of cells at the invasive front of the tumour in three consecutive high-powered fields ( Â 400); each field corresponded to a total number of cells ranging from 300 to 1000. We counted at least 1000 cells per sample.
Cell extraction and Western blotting
Lysates from exponentially growing cell lines were prepared in buffer (20 mM Tris-HCl, pH 7.6, 1 mM EDTA, 140 mM NaCl, 1% Nonidet P-40, 1% aprotinin, 1 mM phenylmethylsulphonyl fluoride, 1 mM sodium vanadate). The protein concentration was determined using a BCA Protein Assay Kit (Pierce, Rockford, IL, USA). Protein (30 mg) from each cell line was resuspended in sodium dodecyl sulphate (SDS) sample buffer (100 mM Tris-HCl, pH 8.8, 0.01% bromophenol blue, 36% glycerol, 4% SDS) containing 1 mM dithiothreitol, boiled for 5 min, and subjected to a 5À10% gradient Ready-Gel (Bio-Rad, Tokyo, Japan). Proteins were electrotransferred to a Hybond-enhanced chemiluminescence nitrocellulose membrane (Amersham Pharmacia Biotech, Buckinghamshire, UK). Proteins were immunoblotted by using anti-FAK (clone 4.47; Upstate Biotechnology). The bands were detected using an enhanced chemiluminescence detection system (Amersham Pharmacia Biotech). For reblotting; membranes were stripped according to the manufacturer's protocol. Proteins were reblotted using anti-FAK [pY 397 ] and anti-b-actin (Sigma). Antib-actin (Sigma) antibody served as the control.
Statistical analysis
Statistical analysis was performed using the unpaired two-group ttest for age, number of lymph node metastases and Ki-index. The w 2 test was used for gender, differentiation, location, and TNM clinical classification. Survival curves were calculated by the Kaplan -Meier method, and analysis was carried out by the logrank test.
RESULTS
Relationship between FAK expression and clinicopathological features FAK expression in ESCC was investigated by immunohistochemical analysis of formalin-fixed, paraffin-embedded specimens using a FAK-specific Mab. In normal oesophageal tissue, immunostaining of FAK was detected in the cytoplasm of the basal cells, parabasal cells, vascular endothelial cells, and leukocytes ( Figure 1A) . Immunostaining of FAK was seen in the cytoplasm of all cancer cells, particularly in cells located in the invasive fronts of the cancer nests ( Figure 1B -D) . As heterogeneous expression of FAK was noted in tumours, samples were classified as FAK overexpression ( þ ) when 440% of carcinoma cells were stained more intensely than the normal epithelial basement membrane. FAK overexpression was detected in 54 of the 91 patients (59.3%). The relationship between the clinicopathological characteristics of patients with ESCC and FAK overexpression is summarized in Table 1 . A significant correlation was observed between FAK overexpression and cell differentiation (P ¼ 0.0057), depth of tumour invasion (P ¼ 0.0023), presence of regional lymph node metastasis (P ¼ 0.0097), number of lymph node metastases (P ¼ 0.0026), and disease stage (P ¼ 0.012). However, there was no significant association with age, sex, tumour location, or presence of distant metastasis.
It was reported that integrin signalling through FAK leads to the regulation of cell proliferation and survival (Schlaepfer et al, 1994; Guan, 1997) . Ki-67 is a useful marker for evaluating the proliferation potential of normal and tumour cells. Therefore, we studied the correlation between the expression of FAK and the Ki-67-labelling index. The mean index in FAK-overexpression ( þ ) patients was 42.4716.0, and higher than that in FAK-overexpression (À) patients (37.8716.7). However, the difference was not significant (P ¼ 0.18).
The survival rates of patients with FAK-overexpression ( þ ) cancer were significantly lower than those of patients with FAKoverexpression (À) cancer (P ¼ 0.006; Figure 2 ). The mean 5-year survival rate of patients without FAK overexpression was 69%, whereas that of patients with FAK overexpression was 38%. Multivariate analysis showed that FAK overexpression was not a prognostic factor by itself, in contrast to depth of tumour invasion, lymph node metastasis, or disease stage (data not shown). We reanalysed the prognosis of patients with the same pathological background. The survival rates of patients with FAK-overexpressing cancer were lower than those of patients without FAKoverexpressing cancer for those at stages T1N0, T1N1, T2N0, T2N1, and T3N1, but the difference was not significant. There was no difference in survival for T3N0 patients.
FAK expression at the protein level and FAK phosphorylation at tyrosine 397 in the cell lines
The expression of FAK at the protein level was investigated in seven cell lines derived from ESCC and one immortalised human keratinocyte cell line. Western blotting revealed different levels of expression of FAK (Figure 3 ; upper panel). FAK was expressed at a high level in TE-1, TE-8, TE-15, and TT cells, at a moderate level in TE-2 and TTn cells, and at a low level in TE-13 and HaCaT cells.
Tyrosine 397 was identified as a major site of FAK autophosphorylation (Schaller et al, 1994) 
DISCUSSION
Our immunohistochemical results suggest that the expression of FAK protein is correlated with cell differentiation, depth of tumour invasion, occurrence of regional lymph node metastasis, and the number of lymph node metastases. FAK overexpression was detected in all cancer cells. In particular, strong expression was observed in invasive tumour fronts. This result indicated that invading cancer cells expressed FAK abundantly. The proliferation activity of tumour with FAK overexpression is higher than that without FAK overexpression, which is not significant statistically. Furthermore, the prognosis of patients who overexpressed FAK was significantly less favourable than that of FAK-overexpression (À) patients. A number of reports have indicated that FAK may be up-regulated in human tumour cells of diverse origin (Weiner et al, 1993; Akasaka et al, 1995; Owens et al, 1995; Tremblay et al, 1996; McCormack et al, 1997; Cance et al, 2000) . In some of these reports, there has been a suspected relationship between FAK expression and metastatic ability (Owens et al, 1995; Tremblay et al, 1996) . These observations support the results of our study. Slack et al demonstrated that an increase in FAK expression, coupled with tyrosine phosphorylation of FAK on tyrosine 861, may contribute to the increased cell motility of highly tumorigenic prostate cancer cells (Slack et al, 2001 ). Overexpression of FAK may alter the motility of ESCC cells, and as a result of this high motility, FAK protein might be overexpressed in those patients with more invasive and metastatic ESCC. Further work is clearly required to investigate the relationship between FAK overexpression and tumour malignancy in ESCC.
FAK-overexpression (−) FAK-overexpression (+)
We investigated the levels of expression of FAK in seven ESCC cell lines and one immortalised human keratinocyte cell line. All ESCC cell lines expressed various levels of FAK and, except for TE-13, the levels were higher than those in the immortalised human keratinocyte cell line. Although immunohistochemical analysis showed a significant correlation between FAK overexpression and poor tumour differentiation, there was no relationship between FAK expression and cell line differentiation. This discrepancy may have been due to differences between the characteristics of the cell lines and the pathological diagnoses of the primary lesions. There was no relationship between FAK overexpression and p53 status in the ESCC cell lines. Galiana et al (1993) have reported that the TE-1, TE-2, and TE-8 cell lines are more highly tumorigenic than TE-13 in nude mice. Our results showed that the FAK level was high in TE-1 and TE-8, intermediate in TE-2, and low in TE-13. From our results, we suspected that overexpression of FAK might be correlated with high tumorigenicity in human ESCC cell lines. In all but one of the ESCC cell lines, the level of FAK phosphorylation at tyrosine 397 was similar to the amount of FAK protein. It is interesting that in TE-15, we detected a low level of phosphorylation at tyrosine 397 of FAK in spite of the abundance of FAK protein. We cannot explain this result, although it might have been caused by the characteristics of TE-15. As the signal intensity of FAK in all cell lines was similar to the amount of FAK protein, we consider that the evaluation of FAK expression might lead indirectly to an evaluation of FAK signal transduction.
It has been reported that the fak gene dosage is increased in a variety of cell lines derived from SCC of the head and neck, lung, breast, and colon cancer (Agochiya et al, 1999) . 25 As our study material was ESCC, the observed overexpression of FAK might have been caused by fak gene amplification.
In our study, patients with FAK overexpression had a poor prognosis for overall survival. However, multivariate statistical analysis showed that FAK overexpression was not a prognostic factor by itself. Therefore, our result was presumably influenced by the factors of cell differentiation, tumour invasion, and lymph node metastasis. Some reports have demonstrated that the degree of cell differentiation is a useful prognostic factor in ESCC patients (Torres et al, 1999; Wang et al, 1999) . Invasion and metastasis, the main causes of death in most cancer patients, remain the most important but least understood aspects of cancer. In particular, the presence of lymph node metastasis and the number of nodal metastases are associated with a poor prognosis in oesophageal cancer (Kuwano et al, 1997; Altorki and Skinner, 2001 ). As FAK overexpression was related to these factors, patients with FAK overexpression had a poor prognosis.
Detection of FAK expression in formaldehyde-fixed paraffinembedded tissue sections by immunohistochemical techniques is easy, low cost, and quantifiable, and reveals the localisation of FAK overexpression. Intense FAK expression in preoperative biopsy specimens may be an indicator of advanced disease with a high probability of tumour spread. FAK may be a good therapeutic target, the manipulation of which may prevent ESCC cells from invading other organs and spreading into the lymphatic drainage.
In conclusion, FAK overexpression is related to cell differentiation, tumour invasiveness, and lymph node metastasis. Consequently, patients whose tumours overexpress FAK have a poorer prognosis than those whose tumours do not.
